Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo
Data May Facilitate Closing Of Pfizer Merger
With accelerated approval in advanced urothelial cancer, the sponsors now have data that could support full approval.
You may also be interested in...
The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.
Merck’s mega-blockbuster delivers a Phase III hit in muscle-invasive urothelial carcinoma in the adjuvant setting, opening the door for an expanded approval that could ultimately impact ultimately impact revenues at later stages.
Keeping Track: Accelerated Approval Wins (Padcev+Keytruda) And Losses (Imbruvica To Shed MCL, MZL Claims)
The latest drug development news and highlights from the Pink Sheet's US FDA Perfomance Tracker.